Agenus (NASDAQ:AGEN) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Agenus (NASDAQ:AGEN) from a buy rating to a hold rating in a research report released on Saturday.

A number of other brokerages have also recently issued reports on AGEN. HC Wainwright upped their target price on Agenus from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Agenus currently has an average rating of “Hold” and a consensus target price of $30.00.

Agenus Price Performance

Shares of Agenus stock opened at $5.01 on Friday. The company’s 50 day moving average price is $3.44 and its two-hundred day moving average price is $3.49. The firm has a market capitalization of $208.62 million, a P/E ratio of 3.15 and a beta of 1.55. Agenus has a fifty-two week low of $2.71 and a fifty-two week high of $8.70.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by ($1.08). Agenus had a negative return on equity of 31.66% and a net margin of 50.49%.The company had revenue of $33.74 million for the quarter, compared to analyst estimates of $129.50 million. On average, analysts expect that Agenus will post 0.83 earnings per share for the current year.

Hedge Funds Weigh In On Agenus

Hedge funds have recently modified their holdings of the business. EP Wealth Advisors LLC acquired a new stake in Agenus in the fourth quarter valued at $31,000. Jump Financial LLC bought a new position in Agenus during the 2nd quarter worth $55,000. R Squared Ltd acquired a new position in Agenus during the 4th quarter worth about $41,000. Squarepoint Ops LLC acquired a new position in Agenus during the 3rd quarter worth about $54,000. Finally, Redwood Family Wealth LLC acquired a new position in Agenus during the 4th quarter worth about $44,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.